LOCORTEN ® Neomycin + Flumetasone

LOCORTEN ® is a drug based on Neomycin sulfate and pivalate Flumetasone

THERAPEUTIC GROUP: Corticosteroids, associations with antiseptics

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Directions LOCORTEN ® Neomicina + Flumetasone

LOCORTEN ® is indicated in the treatment of inflammatory disorders of the skin sensitive to treatment with corticosteroids.

Mechanism of action LOCORTEN ® Neomycin + Flumetasone

Neomicina and Flumetasone, active ingredients of LOCORTEN ®, are elements with different and complementary therapeutic activities that are effective in treating cutaneous inflammatory lesions even when strongly exposed to the risk of bacterial infections. In fact, while Flumetasone, like other synthetic corticosteroids, is able to control the phlogistic evolution of the lesion, reducing the production of inflammatory mediators and the recall and activation of cellular elements involved in the genesis of the symptomatology, Neomycin, antibiotic belonging to the family of Aminoglycosides, is able to inhibit the protein synthesis of Gram positive and Gram negative bacteria, inducing the death of the microorganism. This complete pattern of activity therefore allows to control the symptomatology complained of by the patient, giving at the same time also an active protection against possible bacterial superinfections.

Studies carried out and clinical efficacy

LOCORTON AND DERMATOSIS FROM CORTICOSTEROIDS J Int Med Res. 1987 Sep-Oct; 15 (5): 255-63.

Study demonstrating the excellent therapeutic result obtained starting from the use of LOCORTEN in the treatment of erythema and pruritus in patients with topical corticosteroid dermatitis, with a very rapid improvement in symptoms.

NEW DELIVERY METHODS Int J Pharm. 2009 Mar 31; 370 (1-2): 181-6. doi: 10.1016 / j.ijpharm.2008.11.014. Epub 2008 Nov 27.

Hoeller S, Sperger A, Valenta C.

Yet another pharmacokinetic study that evaluates the efficacy of Lecithin-based nano emulsions in improving drug release topically, ensuring greater therapeutic success.

LOCORTEN IN DENTISTRY Drugs Exp Clin Res. 1985; 11 (8): 523-6.

A dated study that demonstrates the effectiveness of Locorten in the treatment of oral cavity pathologies such as periodontitis, stomatitis and post-prosthesis abscesses, guaranteeing rapid remission of symptoms.

Method of use and dosage

LOCORTEN ® Cream for cutaneous use and ointment with 0.02% of Flivaletasone pivalate and 0.5% of Neomycin sulfate. The doctor should define the modalities of application, the choice of the type of pharmaceutical format and the dosages and the timing based on the general health conditions of the patient and the severity of his clinical picture. Generally, it is recommended to apply the appropriate amount of the drug directly on the treated area 4-6 times a day in the initial phases of the therapy to halve it in the remission phases.

Warnings LOCORTEN ® Neomycin + Flumetasone

The use of LOCORTEN ® should be preceded by a careful medical examination in order to clarify the origin of the lesion and any prescriptive appropriateness. At the same time the patient should respect a series of sanitary regulations useful for optimizing the efficacy of the therapy and limiting the incidence of potential side effects such as cleansing the hands after each application, avoiding the application of the drug on very large areas or in contact with eyes and mucous membranes, avoid use of the occlusive bandage without proper medical prescription, consult a doctor immediately following the appearance of undesirable effects and keep the drug out of the reach of children.

PREGNANCY AND BREASTFEEDING

The contraindications to the use of LOCORTEN ® generally also extend to pregnancy and the subsequent period of breastfeeding, given the potential side effects of systemic corticosteroids for the health of the fetus and infant.

Interactions

At the present time, known pharmacological interactions are not known, although it should be remembered that the simultaneous intake of cytochrome inhibitor drugs may increase blood concentrations of the amount of corticosteroid absorbed.

Contraindications LOCORTEN ® Neomycin + Flumetasone

The use of LOCORTEN ® is contraindicated in patients who are hypersensitive to the active ingredient or to one of its excipients, in patients suffering from inadequately treated viral, bacterial and fungal infections and from atopic dermatitis.

Undesirable effects - Side effects

The therapy with LOCORTEN ®, especially when prolonged for a long time, could determine the onset of local and fortunately transitory side effects such as burning, irritation, itching, dry skin, hypopigmentation and hypertrichosis. Clinically relevant side effects are definitely more rare, such as to require an immediate suspension of the therapy in progress.